×
About 32,387 results

ALLMedicine™ Lymphomas Center

Research & Reviews  15,487 results

The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum o...
https://doi.org/10.1007/s00520-021-06241-6
Supportive Care in Cancer : Official Journal of the Multi... Martinez XU, Chowdhury A et. al.

May 8th, 2021 - Cutaneous lymphomas (CLs) are a group of rare, potentially disfiguring and disabling cancers that can have a significant impact on quality of life (QoL). While previous studies have shown that mycosis fungoides (MF) and Sézary syndrome (SS) impair...

Primary splenic anaplastic variant of diffuse large B-cell lymphoma: a case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101127
Journal of Medical Case Reports; Ismail S, Ali F et. al.

May 6th, 2021 - Primary splenic lymphoma represents a rare entity that constitutes less than 1% of non-Hodgkin lymphomas, and less than 2% of all lymphomas. Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of primary splenic lymphomas...

Methylated markers accurately distinguish primary central nervous system lymphomas (PCN...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097855
Clinical Epigenetics; Downs BM, Ding W et. al.

May 6th, 2021 - Definitive diagnosis of primary central nervous system lymphoma (PCNSL) requires invasive surgical brain biopsy, causing treatment delays. In this paper, we identified and validated tumor-specific markers that can distinguish PCNSL from other CNS ...

see more →

Guidelines  87 results

Off-the-Shelf CAR-T Cell Therapy ALLO-501 Induces High Responses in Relapsed/Refractory B-Cell Lymphomas
https://www.onclive.com/conference-coverage/asco-2020/off-the-shelf-cart-cell-therapy-allo501-induces-high-responses-in-relapsed-refractory-bcell-lymphomas

May 29th, 2020 - The allogeneic chimeric antigen receptor (CAR)-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, has clinical activity and a manageable safety profile in patients with relapsed/refractory large B-cell or follicular lymphoma. T...

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and...
https://doi.org/10.1016/j.annonc.2019.10.010
Annals of Oncology : Official Journal of the European Soc... Zucca E, Arcaini L et. al.

Jan 8th, 2020 - Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Zucca E,Arcaini L,Buske C,Johnson PW,Ponzoni M,|diagnosis,epidemiology,therapy,

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
https://www.sciencedirect.com/science/article/pii/S0923753419354651
Annals of Oncology; Zucca E,et al

Dec 31st, 2019 - This updated ESMO Clinical Practice Guideline provides key recommendations on the management of marginal zone lymphomas.

Diffuse Large B-Cell Lymphoma: ESMO Clinical Practice Guidelines
https://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma
Annals of Oncology; Tilly H et al

Nov 13th, 2019 - Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. The updated ESMO Clinical Practice Guidelines provide information on the current management of diffuse large B-cell lymphoma including recommenda...

see more →

Drugs  85 results see all →

Clinicaltrials.gov  16,081 results

The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum o...
https://doi.org/10.1007/s00520-021-06241-6
Supportive Care in Cancer : Official Journal of the Multi... Martinez XU, Chowdhury A et. al.

May 8th, 2021 - Cutaneous lymphomas (CLs) are a group of rare, potentially disfiguring and disabling cancers that can have a significant impact on quality of life (QoL). While previous studies have shown that mycosis fungoides (MF) and Sézary syndrome (SS) impair...

Primary splenic anaplastic variant of diffuse large B-cell lymphoma: a case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101127
Journal of Medical Case Reports; Ismail S, Ali F et. al.

May 6th, 2021 - Primary splenic lymphoma represents a rare entity that constitutes less than 1% of non-Hodgkin lymphomas, and less than 2% of all lymphomas. Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of primary splenic lymphomas...

Methylated markers accurately distinguish primary central nervous system lymphomas (PCN...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097855
Clinical Epigenetics; Downs BM, Ding W et. al.

May 6th, 2021 - Definitive diagnosis of primary central nervous system lymphoma (PCNSL) requires invasive surgical brain biopsy, causing treatment delays. In this paper, we identified and validated tumor-specific markers that can distinguish PCNSL from other CNS ...

see more →

News  643 results

FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas
https://www.medscape.com/viewarticle/949934

Apr 25th, 2021 - The US Food and Drug Administration granted an accelerated approval April 24 for a new drug for use in patients with relapsed/refractory diffuse large B-cell lymphomas (DLBCL) who have tried at least two prior systemic therapies. The new product, ...

CAR T-cell Products Shine in Real-World Setting, Reveal New Insights
https://www.medscape.com/viewarticle/946240

Feb 21st, 2021 - Real-world experience with chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas compares favorably with experience in commercial and trial settings and provides new insights for predicting outcomes, according to Paolo Corrad...

FDA Approves Umbralisib (Ukoniq) for Two Lymphomas
https://www.medscape.com/viewarticle/945426

Feb 7th, 2021 - The US Food and Drug Administration (FDA) has granted accelerated approval to umbralisib (Ukoniq) for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and...

FDA OKs New CAR T- Cell Tx for Large B-cell Lymphomas
https://www.medscape.com/viewarticle/945417

Feb 4th, 2021 - The US Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi), a chimeric antigen receptor (CAR) T-cell product for the treatment of adults with certain types of relapsed or refractory large B-cell lymphoma who relapse...

Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas
https://www.medscape.com/viewarticle/942195

Dec 7th, 2020 - In patients with T-cell lymphoma, allogeneic transplant can lead to durable remissions among patients who might otherwise have poor outcomes, results of a large retrospective observational study suggest. Five-year progression-free survival (PFS) a...

see more →

Patient Education  4 results see all →